Condition: Down Syndrome · Down Syndrome (DS) · Down Syndrome (Trisomy 21) · Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
The purpose of this study is to evaluate whether levetiracetam can prevent epileptic seizures in patients with Alzheimer's disease associated with Down syndrome. It will also analyze whether it can delay the neurodegeneration associated with this disease. Patients will be randomly assigned to one of two groups: one group will receive the active drug (levetiracetam), and the other will receive a placebo. Both groups will receive the treatment for 96 weeks. Each patient will participate for a total of 2 years and 5 months.
This description comes directly from the study's public registry record.
María Carmona Iragui, Doctor · +34 93 556 59 56 · mcarmonai@santpau.cat
Diego Real de Asúa Cruzat, Doctor · diego.realdeasua@salud.madrid.org
Always discuss trial participation with your own doctor first.
| Hospital Virgen de las Nieves | Granada, Andalusia, Spain | Not Yet Recruiting |
| Fundación CITA Alzheimer | Donostia / San Sebastian, Basque Country, Spain | Not Yet Recruiting |
| Hospital Universitario Marqués de Valdecilla | Santander, Cantabria, Spain | Not Yet Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Catalonia, Spain | Recruiting |
| Hospital La Princesa | Madrid, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07234695